Replimune Group, Inc.

NasdaqGS:REPL Aktierapport

Börsvärde: US$1.0b

Replimune Group Förvaltning

Förvaltning kriterier kontrolleras 2/4

Replimune Group VD är Sush Patel, utsedd i Apr 2024, har en mandatperiod på 2.33 år. totala årliga ersättningen är $ 5.85M, bestående av 12% lön 88% bonusar, inklusive företagsaktier och optioner. äger direkt 0.14% av företagets aktier, värda $ 1.44M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 2.3 år respektive 5.5 år.

Viktig information

Sush Patel

Verkställande direktör

US$5.8m

Total ersättning

VD-lön i procent11.97%
Anställning som VD2.3yrs
Ägande av VD0.1%
Ledningens genomsnittliga anställningstid2.3yrs
Styrelsens genomsnittliga mandatperiod5.5yrs

Senaste uppdateringar av ledningen

Recent updates

Seeking Alpha • Jul 30

Replimune: 'Sell' Continued Doubt On Single-Arm IGNYTE Trial For RP1 FDA Review

Summary Replimune Group, Inc. is downgraded to Sell ahead of the FDA Adcom vote on RP1 + OPDIVO for advanced melanoma. FDA briefing documents highlight persistent concerns: reliance on single-arm IGNYTE trial, lack of control arm, and questionable risk/benefit profile. Despite promising 3-year OS data [47.8% alive], briefing documents and two prior CRLs cast significant doubt on approval prospects. REPL faces a cash crunch, burning ~$73M per quarter, with funding only into its calendar Q1 2027 and potential dilution or asset sales looming. Read the full article on Seeking Alpha
Analysartikel • Feb 08

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysartikel • Aug 01

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Apr 28

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Summary Replimune Group, Inc.'s BLA of RP1 + OPDIVO in advanced melanoma received an FDA Priority Review, with a PDUFA date set for July 22, 2025. RP2, adding an anti-CTLA-4 component, is being tested in metastatic uveal melanoma and 2nd-line metastatic hepatocellular carcinoma patients. Financially, Replimune has $536.5 million in cash, but REPL will likely need additional funding within the next 12 months. The global liver cancer drugs market is expected to reach $14.9 billion by 2031. Read the full article on Seeking Alpha
Analysartikel • Apr 11

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Feb 12

Replimune: A Misunderstood Contender In Oncolytics

Summary Replimune Group's solid cash position and strategic focus on niche oncology markets position it for potential success, despite market volatility and past trial setbacks. The company's RP1 and RP2 platforms target unmet needs in melanoma and other cancers, with promising data and regulatory momentum supporting their potential. The FDA's Priority Review and Breakthrough Therapy designations for RP1 underscore its potential to reshape second-line melanoma treatment and expedite market entry. Despite skepticism about oncolytic viruses, Replimune's approach and collaborations with big pharma could yield significant commercial opportunities if clinical data remains strong. Read the full article on Seeking Alpha
Seeking Alpha • Nov 29

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Summary Replimune has submitted its BLA of RP1 + Opdivo for the treatment of advanced melanoma patients previously treated with an anti-PD1 containing regimen. The phase 3 confirmatory IGNYTE-3 study is underway to prove yet again that RP1 + Opdivo is able to help these patients with advanced melanoma and to keep the drug marketed. The global melanoma therapeutics market size is projected to reach $17.93 billion by 2034. RP2 is another drug in the company's pipeline which is being developed other than target metastatic uveal melanoma and Hepatocellular Carcinoma patients. Read the full article on Seeking Alpha
Analysartikel • Nov 23

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Sep 03

Replimune: Strong Data In A Highly Differentiated Space

Summary Replimune's RP1, an oncolytic immuno-gene therapy, shows promise with a 31.4% ORR in phase 2 trials for post PD-1 melanoma and non-melanoma skin cancers. RP2, adding an anti-CTLA-4 component to RP1, demonstrated a 29.4% ORR in phase 1 trials, with durable responses in difficult-to-treat tumors. Despite competitive challenges and a failed CSCC trial, Replimune's cash runway supports its accelerated approval and phase 3 trials, making it an attractive investment. RP1 and RP2 together could be a game-changer, offering a compelling opportunity at current low stock prices. Read the full article on Seeking Alpha
Analysartikel • Aug 16

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • May 22

Replimune: Continuing To Justify The Bear Thesis (For Now)

Summary Replimune Group, Inc.'s stock has fallen 35% in 2024, and an inflection point is not expected yet. The company is working on RP1, an oncolytic virus therapy, and has shared positive results from their ARTACUS trial. Replimune plans to submit a BLA for RP1 approval in melanoma, but this is far from guaranteed, especially in 2024. Read the full article on Seeking Alpha
Analysartikel • Feb 06

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha • Jan 23

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Summary Replimune Group is developing virus-based treatments for solid tumors, particularly skin cancer. The company's RP1 treatment did not show significant improvement in response rates compared to standard care in a phase 1/2 study, though there is a signal of something buried therein. Replimune plans to initiate a confirmatory study for RP1 in melanoma patients and is also developing RP2 for uveal melanoma. Read the full article on Seeking Alpha
Analysartikel • Dec 25

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Key Insights The projected fair value for Replimune Group is US$9.64 based on 2 Stage Free Cash Flow to Equity Current...
Analysartikel • Jul 13

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Analys av ersättningar till VD

Hur har Sush Patel:s ersättning förändrats jämfört med Replimune Group:s resultat?
DatumTotal ersättningLönFöretagets resultat
Mar 31 2026US$6mUS$700k

-US$314m

Dec 31 2025n/an/a

-US$315m

Sep 30 2025n/an/a

-US$310m

Jun 30 2025n/an/a

-US$280m

Mar 31 2025US$4mUS$600k

-US$247m

Dec 31 2024n/an/a

-US$228m

Sep 30 2024n/an/a

-US$213m

Jun 30 2024n/an/a

-US$220m

Mar 31 2024US$2mUS$465k

-US$216m

Dec 31 2023n/an/a

-US$210m

Sep 30 2023n/an/a

-US$199m

Jun 30 2023n/an/a

-US$182m

Mar 31 2023US$3mUS$447k

-US$174m

Dec 31 2022n/an/a

-US$157m

Sep 30 2022n/an/a

-US$147m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022US$7mUS$394k

-US$118m

Ersättning vs marknad: Sush s total kompensation ($USD 5.85M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 3.54M ).

Ersättning vs inkomst: Ersättningen för Sush har ökat samtidigt som företaget är olönsamt.

VD OCH KONCERNCHEF

Sush Patel (55 yo)

2.3yrs
Anställning
US$5,845,982
Kompensation

Dr. Sushil Patel, also known as Sush, Ph D., is Independent Director of Revolution Medicines, Inc. from June 16, 2022. Dr. Patel is CEO & Director of Replimune Group, Inc. from April 1, 2024.Dr. Patel ser...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Sushil Patel
CEO & Director2.3yrsUS$5.85m0.14%
$ 1.4m
Emily Hill
Chief Financial Officer2.9yrsUS$2.09m0.070%
$ 707.2k
Konstantinos Xynos
Chief Medical Officer3.7yrsUS$2.11m0.073%
$ 744.2k
Philip Astley-Sparke
Executive Chairman11.6yrsUS$6.02m1.58%
$ 16.0m
Andrew Schwendenman
Chief Accounting Officer & Treasurer3.3yrsinga uppgifter0.030%
$ 300.3k
Shawn Glidden
Senior VP & General Counsel1.5yrsinga uppgifteringa uppgifter
Camilo Garcia
Chief Human Resource Officer1.5yrsinga uppgifteringa uppgifter
Paul Bullock
Chief Manufacturing Officer & Framingham Site Head2.6yrsinga uppgifteringa uppgifter
Nina Aragam
Senior Vice President of Portfolio Strategy & Program Management1.5yrsinga uppgifteringa uppgifter
Carolyn Trott
Senior Vice President of Quality Assurance2.3yrsinga uppgifteringa uppgifter
Kari Jeschke
Senior Vice President of Regulatory Affairs1.5yrsinga uppgifteringa uppgifter
2.3yrs
Genomsnittlig anställningstid
55yo
Genomsnittlig ålder

Erfaren ledning: REPL s ledningsgrupp anses vara erfaren ( 2.3 års genomsnittlig anställningstid).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Sushil Patel
CEO & Director2.3yrsUS$5.85m0.14%
$ 1.4m
Philip Astley-Sparke
Executive Chairman11.6yrsUS$6.02m1.58%
$ 16.0m
Joseph Slattery
Independent Director8.8yrsUS$251.11k0.0079%
$ 80.4k
Michael Goller
Independent Director1.4yrsUS$50.00k0%
$ 0
Paolo Pucci
Independent Director6.3yrsUS$236.11k0%
$ 0
Madhavan Balachandran
Independent Director1.9yrsUS$231.11k0%
$ 0
Kapil Dhingra
Independent Director9.1yrsUS$246.11k0%
$ 0
Christy Oliger
Independent Director4.7yrsUS$246.11k0%
$ 0
Dieter Weinand
Lead Independent Director8.2yrsUS$278.61k0%
$ 0
Veleka Peeples-Dyer
Independent Director3.2yrsUS$238.61k0%
$ 0
5.5yrs
Genomsnittlig anställningstid
58.5yo
Genomsnittlig ålder

Erfaren styrelse: REPL s styrelse anses vara erfaren ( 5.5 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/08/10 10:20
Aktiekurs vid dagens slut2026/08/10 00:00
Intäkter2026/03/31
Årlig intjäning2026/03/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Replimune Group, Inc. bevakas av 13 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Clarence PowellBMO Capital Markets Equity Research
Evan SeigermanBMO Capital Markets Equity Research
Guyn KimBMO Capital Markets Equity Research